Li Wan-Hong, Ma Wan-Jing, Zhang Wei, Zhao Shu-Ning, Zhao Xin-Miao, Ma Chen-Hao, Xi Ming-Ze, Sun Hui
Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, 150081, China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Pharmaceutical Experiment Teaching Center, College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Eur J Pharmacol. 2025 Sep 15;1003:177934. doi: 10.1016/j.ejphar.2025.177934. Epub 2025 Jul 8.
Pulmonary arterial hypertension (PAH) is a chronic and progressive pulmonary vascular disease with an extremely high mortality rate. The pathogenesis of PAH is characterized by a progressive increase in vascular resistance due to the excessive proliferation of pulmonary arterial endothelial cells and pulmonary artery smooth muscle cells, which leads to uncompensated remodeling of the right ventricle and, ultimately, right heart failure. However, the molecular mechanisms behind pulmonary arterial hypertension have been much elucidated, but effective therapeutic agents are rare. Programmed cell death (PCD) is an intrinsic cellular process tightly regulated by specific genetic mechanisms, which is usually identified with apoptosis, autophagy, but its scope has been gradually expanded with pyroptosis, ferroptosis, and necroptosis. Both traditional forms of PCD and novel forms have been implicated in the pathogenesis of PAH. In order to gain a more comprehensive understanding of the pathogenesis and progression of PCD in PAH, this review comprehensively summarized the association between various PCDs and PAH and discussed the role of endothelial and smooth muscle cells in this, as well as the crosstalk, which will contribute to the development of innovative and targeted diagnostic and therapeutic approaches.
肺动脉高压(PAH)是一种慢性进行性肺血管疾病,死亡率极高。PAH的发病机制表现为肺动脉内皮细胞和肺动脉平滑肌细胞过度增殖导致血管阻力逐渐增加,进而引起右心室失代偿性重塑,最终导致右心衰竭。然而,肺动脉高压背后的分子机制尚未完全阐明,有效的治疗药物也很少。程序性细胞死亡(PCD)是一种由特定遗传机制严格调控的内在细胞过程,通常与凋亡、自噬相关,但随着焦亡、铁死亡和坏死性凋亡的发现,其范围逐渐扩大。传统形式的PCD和新形式的PCD都与PAH的发病机制有关。为了更全面地了解PAH中PCD的发病机制和进展,本综述全面总结了各种PCD与PAH之间的关联,并讨论了内皮细胞和平滑肌细胞在此过程中的作用以及它们之间的相互作用,这将有助于开发创新的靶向诊断和治疗方法。